[en] Corticotropin-releasing factor (CRF) is well known for its role in the hypothalamic-pituitary-adrenocortical (HPA) axis and its involvement in stress and anxiety. CRF acts via two main receptor subtypes, CRF(1) and CRF(2). Other endogenous CRF-related peptide ligands are the Urocortins 1 and 2 and Stresscopin. While CRF is thought to mediate its anxiogenic-like properties through CRF(1), the role of CRF(2) and its endogenous ligands Urocortin 2 and Stresscopin are less clear, with a suggested role in mediating the delayed effects of stress. Measurement of local cerebral glucose utilization (LCGU) provides an estimate of neuronal activity, and is of potential use as a translational tool in comparison to FDG PET. We hypothesized that comparison of the patterns of metabolic changes induced by CRF-related peptides could provide further information on their role in the brain. The present studies examined the effects of CRF-related peptides on LCGU, and the role of CRF(1) and CRF(2) in the CRF-induced LCGU response. CRF induced increases in LCGU in hypothalamic, thalamic, cerebellar and hippocampal regions, and further studies using antagonists or mutant mice lacking a functional CRF(1) receptor clearly suggested a role for CRF(2) in this effect. Urocortin 1 increased LCGU in a dissected hindbrain region. However, central administration of the CRF(2)-selective agonists Urocortin 2 and Stresscopin failed to affect LCGU, which may suggest ligand-dependent receptor activation within the CRF system. The present data supports a role for CRF(2) in the regulation of neuronal glucose metabolism.
Disciplines :
Life sciences: Multidisciplinary, general & others
Author, co-author :
Warnock, Geoffrey ; Université de Liège - ULiège > Centre de recherches du cyclotron
Moechars, Dieder
Langlois, Xavier
Steckler, Thomas
Language :
English
Title :
In vivo evidence for ligand-specific receptor activation in the central CRF system, as measured by local cerebral glucose utilization.
Bale T.L., Picetti R., Contarino A., Koob G.F., Vale W.W., and Lee K.F. Mice deficient for both corticotropin-releasing factor receptor 1 (CRFR1) and CRFR2 have an impaired stress response and display sexually dichotomous anxiety-like behavior. J Neurosci 22 January (1) (2002) 193-199
Bale T.L., and Vale W.W. CRF and CRF receptors: role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol 44 (2004) 525-557
Benoit S.C., Thiele T.E., Heinrichs S.C., Rushing P.A., Blake K.A., and Steeley R.J. Comparison of central administration of corticotropin-releasing hormone and urocortin on food intake, conditioned taste aversion, and c-Fos expression. Peptides 21 March (3) (2000) 345-351
Berger H., Heinrich N., Wietfeld D., Bienert M., and Beyermann M. Evidence that corticotropin-releasing factor receptor type 1 couples to Gs- and Gi-proteins through different conformations of its J-domain. Br J Pharmacol 149 December (7) (2006) 942-947
Beyermann M., Rothemund S., Heinrich N., Fechner K., Furkert J., Dathe M., et al. A role for a helical connector between two receptor binding sites of a long-chain peptide hormone. J Biol Chem 275 February (8) (2000) 5702-5709
Bishop G.A., Seelandt C.M., and King J.S. Cellular localization of corticotropin releasing factor receptors in the adult mouse cerebellum. Neuroscience 101 4 (2000) 1083-1092
Bittencourt J.C., and Sawchenko P.E. Do centrally administered neuropeptides access cognate receptors? An analysis in the central corticotropin-releasing factor system. J Neurosci 20 February (3) (2000) 1142-1156
Butler P.D., Weiss J.M., Stout J.C., and Nemeroff C.B. Corticotropin-releasing factor produces fear-enhancing and behavioral activating effects following infusion into the locus coeruleus. J Neurosci 10 January (1) (1990) 176-183
Carli M., Robbins T.W., Evenden J.L., and Everitt B.J. Effects of lesions to ascending noradrenergic neurones on performance of a 5-choice serial reaction task in rats; implications for theories of dorsal noradrenergic bundle function based on selective attention and arousal. Behav Brain Res 9 September (3) (1983) 361-380
Chaki S., Nakazato A., Kennis L., Nakamura M., Mackie C., Sugiura M., et al. Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/CRA0450. Eur J Pharmacol 485 February (1-3) (2004) 145-158
Chen A., Brar B., Choi C.S., Rousso D., Vaughan J., Kuperman Y., et al. Urocortin 2 modulates glucose utilization and insulin sensitivity in skeletal muscle. Proc Natl Acad Sci USA 103 October (44) (2006) 16580-16585
Chen R., Lewis K.A., Perrin M.H., and Vale W.W. Expression cloning of a human corticotropin-releasing-factor receptor. Proc Natl Acad Sci USA 90 October (19) (1993) 8967-8971
Dautzenberg F.M., and Hauger R.L. The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol Sci 23 February (2) (2002) 71-77
de Groote L., Penalva R.G., Flachskamm C., Reul J.M., and Linthorst A.C. Differential monoaminergic, neuroendocrine and behavioural responses after central administration of corticotropin-releasing factor receptor type 1 and type 2 agonists. J Neurochem 94 July (1) (2005) 45-56
Dube T., Brunson T., Nehlig A., and Baram T.Z. Activation of specific neuronal circuits by corticotropin releasing hormone as indicated by c-fos expression and glucose metabolism. J Cereb Blood Flow Metab 20 October (10) (2000) 1414-1424
Dunn A.J., and Berridge C.W. Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses?. Brain Res -Brain Res Rev 15 May (2) (1990) 71-100
Freo U., Ori C., Weiss S.R., and Perini G.I. Time- and dose-dependent effects of corticotropin releasing factor on cerebral glucose metabolism in rats. J Neural Transm 112 November (11) (2005) 1447-1462
Giorgi O., Lecca D., Piras G., Driscoll P., and Corda M.G. Dissociation between mesocortical dopamine release and fear-related behaviours in two psychogenetically selected lines of rats that differ in coping strategies to aversive conditions. Eur J Neurosci 17 June (12) (2003) 2716-2726
Gounko N.V., Kalicharan D., Rybakin V., Gramsbergen A., and van der Want J.J. The dynamic developmental localization of the full-length corticotropin-releasing factor receptor type 2 in rat cerebellum. Eur J Neurosci 23 June (12) (2006) 3217-3224
Henry B., Vale W., and Markou A. The effect of lateral septum corticotropin-releasing factor receptor 2 activation on anxiety is modulated by stress. J Neurosci 26 September (36) (2006) 9142-9152
Hoare S.R., Sullivan S.K., Fan J., Khongsaly K., and Grigoriadis D.E. Peptide ligand binding properties of the corticotropin-releasing factor (CRF) type 2 receptor: pharmacology of endogenously expressed receptors, G-protein-coupling sensitivity and determinants of CRF2 receptor selectivity. Peptides 26 March (3) (2005) 457-470
Hoare S.R., Sullivan S.K., Schwarz D.A., Ling N., Vale W.W., Crowe P.D., et al. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists. Biochemistry 43 April (13) (2004) 3996-4011
Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. [Review] [163 refs]. J Psychiat Res 33 May (3) (1999) 181-214
Hsu S.Y., and Hsueh A.J. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med 7 May (5) (2001) 605-611
Inglis W.L., Olmstead M.C., and Robbins T.W. Selective deficits in attentional performance on the 5-choice serial reaction time task following pedunculopontine tegmental nucleus lesions. Behav Brain Res 123 September (2) (2001) 117-131
Ingram C.D. Pathways and transmitter interactions mediating an integrated stress response. In: Steckler T., Kalin N.H., and Reul J.M.H.M. (Eds). Handbook of stress and the brain (2005), Elsevier, Amsterdam 609-639
Jones D.N.C., Kortekaas R., Slade P.D., Middlemiss D.N., and Hagan J.J. The behavioural effects of corticotropin-releasing factor-related peptides in rats. Psychopharmacologia 138 July (2) (1998) 124-132
Keck M.E., and Holsboer F. Hyperactivity of CRH neuronal circuits as a target for therapeutic interventions in affective disorders. [Review] [101 refs]. Peptides 22 May (5) (2001) 835-844
Lovenberg T.W., Liaw C.W., Grigoriadis D.E., Clevenger W., Chalmers D.T., De Souza E.B., et al. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci USA 92 January (3) (1995) 836-840
Maruyama H., Makino S., Noguchi T., Nishioka T., and Hashimoto K. Central type 2 corticotropin-releasing hormone receptor mediates hypothalamic-pituitary-adrenocortical axis activation in the rat. Neuroendocrinology 86 1 (2007) 1-16
O'Gorman S., Dagenais N.A., Qian M., and Marchuk Y. Protamine-Cre recombinase transgenes efficiently recombine target sequences in the male germ line of mice, but not in embryonic stem cells. Proc Natl Acad Sci USA 94 December (26) (1997) 14602-14607
Pelleymounter M.A., Joppa M., Carmouche M., Cullen M.J., Brown B., Murphy B., et al. Role of corticotropin-releasing factor (CRF) receptors in the anorexic syndrome induced by CRF. J Pharmacol Exp Ther 293 June (3) (2000) 799-806
Pelleymounter M.A., Joppa M., Ling N., and Foster A.C. Pharmacological evidence supporting a role for central corticotropin-releasing factor(2) receptors in behavioral, but not endocrine, response to environmental stress. J Pharmacol Exp Ther 302 July (1) (2002) 145-152
Pelleymounter M.A., Joppa M., Ling N., and Foster A.C. Behavioral and neuroendocrine effects of the selective CRF(2) receptor agonists urocortin II and urocortin III. Peptides 25 April (4) (2004) 659-666
Perrin M.H., and Vale W.W. Corticotropin releasing factor receptors and their ligand family. Ann NY Acad Sci 885 October (1999) 312-328
Phillips R.G., and LeDoux J.E. Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behav Neurosci 106 April (2) (1992) 274-285
Risbrough V.B., Hauger R.L., Pelleymounter M.A., and Geyer M.A. Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice. Psychopharmacology 170 November (2) (2003) 178-187
Risbrough V.B., Hauger R.L., Roberts A.L., Vale W.W., and Geyer M.A. Corticotropin-releasing factor receptors CRF1 and CRF2 exert both additive and opposing influences on defensive startle behavior. J Neurosci 24 July (29) (2004) 6545-6552
Rivier C.L., and Plotsky P.M. Mediation by corticotropin releasing factor (CRF) of adenohypophysial hormone secretion. Annu Rev Physiol 48 (1986) 475-494
Ruhmann A., Bonk I., Lin C.R., Rosenfeld M.G., and Spiess J. Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): development of CRFR2beta-selective antisauvagine-30. Proc Natl Acad Sci USA 95 December (26) (1998) 15264-15269
Sharkey J., Appel N.M., and De Souza E.B. Alterations in local cerebral glucose utilization following central administration of corticotropin-releasing factor in rats. Synapse 4 1 (1989) 80-87
Skelton K.H., Nemeroff C.B., Knight D.L., and Owens M.J. Chronic administration of the triazolobenzodiazepine alprazolam produces opposite effects on corticotropin-releasing factor and urocortin neuronal systems. J Neurosci 20 February (3) (2000) 1240-1248
Steckler T. CRF antagonists as novel treatment strategies for stress-related disorders. In: Steckler T., Kalin N.H., and Reul J.M.H.M. (Eds). Handbook of stress and the brain vol. 15 (2005), Elsevier 373-407
Steckler T., and Dautzenberg F.M. Corticotropin-releasing factor receptor antagonists in affective disorders and drug dependence-an update. CNS Neurol Disord Drug Targets 5 April (2) (2006) 147-165
Steckler T., and Holsboer F. Corticotropin-releasing hormone receptor subtypes and emotion. Biol Psychiatry 46 December (11) (1999) 1480-1508
Steckler T., Inglis W., Winn P., and Sahgal A. The pedunculopontine tegmental nucleus: a role in cognitive processes?. Brain Res -Brain Res Rev 19 August (3) (1994) 298-318
Sullivan R.M., and Gratton A. Prefrontal cortical regulation of hypothalamic-pituitary-adrenal function in the rat and implications for psychopathology: side matters. Psychoneuroendocrinology 27 January (1/2) (2002) 99-114
Takahashi L.K. Role of CRF(1) and CRF(2) receptors in fear and anxiety. Neurosci Biobehav Rev 25 December (7/8) (2001) 627-636
Takahashi L.K. CRF2 receptors: an emerging role of anxiety. Drug News Perspect 15 2 (2002) 97-101
Tanaka Y., Makino S., Noguchi T., Tamura K., Kaneda T., and Hashimoto K. Effect of stress and adrenalectomy on urocortin II mRNA expression in the hypothalamic paraventricular nucleus of the rat. Neuroendocrinology 78 July (1) (2003) 1-11
Timpl P., Spanagel R., Sillaber I., Kresse A., Reul J.M., Stalla G.K., et al. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet 19 June (2) (1998) 162-166
Todorovic C., Radulovic J., Jahn O., Radulovic M., Sherrin T., Hippel C., et al. Differential activation of CRF receptor subtypes removes stress-induced memory deficit and anxiety. Eur J Neurosci 25 June (11) (2007) 3385-3397
Urban J.D., Clarke W.P., von Zastrow M., Nichols D.E., Kobilka B., Weinstein H., et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320 January (1) (2007) 1-13
Usher M., Cohen J.D., Servan-Schreiber D., Rajkowski J., and Aston-Jones G. The role of locus coeruleus in the regulation of cognitive performance. Science 283 January (5401) (1999) 549-554
Valdez G.R., Inoue K., Koob G.F., Rivier J., Vale W., and Zorrilla E.P. Human urocortin II: mild locomotor suppressive and delayed anxiolytic-like effects of a novel corticotropin-releasing factor related peptide. Brain Res 943 July (1) (2002) 142-150
Valdez G.R., Zorrilla E.P., Rivier J., Vale W.W., and Koob G.F. Locomotor suppressive and anxiolytic-like effects of urocortin 3, a highly selective type 2 corticotropin-releasing factor agonist. Brain Res 980 August (2) (2003) 206-212
Vale W., Spiess J., Rivier C., and Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 213 September (4514) (1981) 1394-1397
Van Pett K., Viau V., Bittencourt J.C., Chan R.K., Li H.Y., Arias C., et al. Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol 428 December (2) (2000) 191-212
Warnock G., Prickaerts J., and Steckler T. In: Levin E.D. (Ed). Interactions between CRF and acetylcholine in the modulation of cognitive behaviour (2006), Neurotransmitter Interactions and Cognitive Functions 41-63
Wattler S., Kelly M., and Nehls M. Construction of gene targeting vectors from lambda KOS genomic libraries. Biotechniques 26 6 (1999) 1150-1156 1158, 1160
